Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Waltham, MA, that is focused on developing innovative treatments for peripheral neuropathies. Their lead compound, ricolinostat ACY-1215, is a selective inhibitor of the microtubule modifying enzyme HDAC6, with the potential to restore normal nerve function. Through their research and clinical trials, Regenacy aims to provide lasting relief for patients suffering from diabetic, chemotherapy-induced, and inherited peripheral neuropathies. With a strong emphasis on disease-modifying approaches, Regenacy Pharmaceuticals is dedicated to going beyond pain management to restore peripheral nerve function. Their proprietary portfolio of selective HDAC1,2 inhibitors also holds promise for treating cancer, hemoglobinopathies, and cognitive dysfunction. Founded in 2016, Regenacy Pharmaceuticals acquired exclusive rights to ricolinostat, a clinical stage HDAC6 selective inhibitor, and is committed to advancing the development of novel therapies for peripheral neuropathies and other non-cancer disease indications.
Generated from the website